{"schema_version":"1.0","type":"article","title":"FDA AI 副局長仍待官宣：新藥估值先看證據鏈","url":"https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.md","lang":"zh-Hant","date":"2026-09-07","publish_at":"2026-09-07T08:00:00+08:00","updated_at":"2026-09-07","category":"商業分析系列","topic":"商業分析系列","tags":["FDA","AI 審評","AI 製藥","監管科學"],"summary":"一則「FDA 將增設 AI 副局長」的消息，這幾天讓 AI 製藥圈非常興奮。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"圖 1｜FDA AI 副局長尚未官宣，AI 審評制度已經先行","url":"https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/01_%E5%B0%81%E9%9D%A2_FDA%E5%B0%9A%E6%9C%AA%E5%AE%98%E5%AE%A3AI%E5%89%AF%E5%B1%80%E9%95%B7.png"},{"alt":"圖 2｜FDA 的三條 AI 軌道：內部工具、申報證據、AI 醫材","url":"https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/02_three_tracks_zh_r2.png"},{"alt":"圖 3｜AI 模型進入藥物申報前的七道可信度關卡","url":"https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/03_credibility_steps_zh_r3.png"},{"alt":"圖 4｜投資人應看的不是 AI 標籤，而是可監管的證據鏈","url":"https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/04_evidence_chain_zh_r3.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/00_cover_no_text_r1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-07）。FDA AI 副局長仍待官宣：新藥估值先看證據鏈。https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}